Lumos Pharma (NASDAQ:LUMO) & ALX Oncology (NASDAQ:ALXO) Head to Head Contrast
Lumos Pharma (NASDAQ:LUMO) & ALX Oncology (NASDAQ:ALXO) Head to Head Contrast
Lumos Pharma (NASDAQ:LUMO – Get Rating) and ALX Oncology (NASDAQ:ALXO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
卢莫斯医药(纳斯达克：Lumo-Get评级)和ALX肿瘤学(纳斯达克：ALXO-GET评级)都是小盘医疗公司，但哪只股票更优越？我们将根据这两家公司的盈利能力、机构所有权、收益、风险、估值、分析师建议和股息等方面的实力进行对比。
Profitability
盈利能力
This table compares Lumos Pharma and ALX Oncology's net margins, return on equity and return on assets.
此表比较了Lumos Pharma和ALX Oncology的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Lumos Pharma | N/A | -33.81% | -29.78% |
| ALX Oncology | N/A | -31.38% | -29.66% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 卢莫斯制药公司 | 不适用 | -33.81% | -29.78% |
| ALX肿瘤学 | 不适用 | -31.38% | -29.66% |
Volatility & Risk
波动性与风险
Lumos Pharma has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500.
Lumos Pharma的贝塔系数为1.23，这意味着其股价的波动性比标准普尔500指数高23%。相比之下，ALX Oncology的贝塔系数为2.21，这意味着其股价的波动性比标准普尔500指数高121%。
Analyst Ratings
分析师评级
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lumos Pharma | 0 | 0 | 3 | 0 | 3.00 |
| ALX Oncology | 0 | 1 | 6 | 0 | 2.86 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 卢莫斯制药公司 | 0 | 0 | 3 | 0 | 3.00 |
| ALX肿瘤学 | 0 | 1 | 6 | 0 | 2.86 |
Lumos Pharma presently has a consensus target price of $24.00, suggesting a potential upside of 181.03%. ALX Oncology has a consensus target price of $39.83, suggesting a potential upside of 199.50%. Given ALX Oncology's higher probable upside, analysts plainly believe ALX Oncology is more favorable than Lumos Pharma.
Lumos Pharma目前的共识目标价为24美元，暗示潜在上涨181.03%。ALX Oncology的共识目标价为39.83美元，暗示潜在上涨199.50%。鉴于ALX肿瘤学更有可能上行，分析师们显然认为ALX肿瘤学比Lumos Pharma更有利。
Institutional & Insider Ownership
机构与内部人持股
28.4% of Lumos Pharma shares are owned by institutional investors. Comparatively, 89.4% of ALX Oncology shares are owned by institutional investors. 21.2% of Lumos Pharma shares are owned by company insiders. Comparatively, 49.9% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Lumos Pharma 28.4%的股份由机构投资者持有。相比之下，ALX Oncology 89.4%的股份由机构投资者持有。Lumos Pharma 21.2%的股份由公司内部人士持有。相比之下，ALX Oncology 49.9%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、对冲基金和捐赠基金相信，一家公司的长期表现将好于大盘。
Valuation & Earnings
估值与收益
This table compares Lumos Pharma and ALX Oncology's gross revenue, earnings per share (EPS) and valuation.
此表比较了Lumos Pharma和ALX Oncology的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lumos Pharma | $230,000.00 | 311.90 | -$30.43 million | ($3.44) | -2.48 |
| ALX Oncology | $1.18 million | 459.27 | -$83.46 million | ($2.72) | -4.89 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 卢莫斯制药公司 | $230,000.00 | 311.90 | -3043万美元 | ($3.44) | -2.48 |
| ALX肿瘤学 | 118万美元 | 459.27 | -8,346万元 | ($2.72) | -4.89 |
Lumos Pharma has higher earnings, but lower revenue than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.
Lumos Pharma的收益高于ALX肿瘤学，但营收低于ALX肿瘤学。ALX Oncology的市盈率低于Lumos Pharma，这表明它目前是两只股票中更负担得起的一只。
Summary
摘要
ALX Oncology beats Lumos Pharma on 10 of the 13 factors compared between the two stocks.
与Lumos Pharma相比，ALX Oncology在13个因素中有10个击败了Lumos Pharma。
About Lumos Pharma
关于Lumos Pharma
(Get Rating)
(获取评级)
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Lumos制药公司是一家临床阶段的生物制药公司，专注于罕见疾病治疗药物的开发和商业化。它的主要候选治疗药物Lum-201是一种口服生长激素促分泌剂布洛莫伦，该药正处于第二阶段临床试验，用于治疗儿童生长激素缺乏症和其他罕见的内分泌疾病。该公司总部设在得克萨斯州奥斯汀。
About ALX Oncology
关于ALX肿瘤学
(Get Rating)
(获取评级)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
ALX Oncology Holdings Inc.是一家临床阶段的免疫肿瘤学公司，专注于为抗癌患者开发疗法。它的主要候选产品是ALX148，这是一种CD47阻断疗法，处于1b/2期临床试验，用于治疗骨髓增生异常综合征；用于治疗急性髓系白血病和非霍奇金淋巴瘤，以及一系列实体肿瘤适应症，包括头颈部鳞状细胞癌、人表皮生长因子受体2(HER2)阳性的胃/胃食道交界癌、HER2表达的乳腺癌和其他实体肿瘤。该公司的临床前产品包括Alta-002，一种SIRPA TRAAC，提供对癌症的先天和适应性免疫反应的方法。ALX Oncology Holdings Inc.与默克公司签署了一项合作协议，将对ALX148与培布罗珠单抗联合治疗头颈部癌症的患者进行第二阶段试验；ZymeWorks公司与默克公司签订了一项第一阶段试验，对ALX148与HER2靶向双特异性抗体zanidatamab在乳腺癌和其他实体肿瘤患者中的应用进行评估；Tallac Treeutics公司负责一种新型癌症免疫疗法的开发、制造和商业化。它还与Selexis SA和Crystal Bioscience，Inc.签署了许可协议。该公司成立于2015年，总部位于加利福尼亚州旧金山南部。
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受Lumos Pharma Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收Lumos Pharma和相关公司的最新新闻和分析师评级的每日摘要。